Science, Scientific Research, Rare Disease.
treat as many patients as we could.” Kakkis argued that regulators should allow drugmakers to follow biomarkers as “a more accurate way to measure disease activity than many clinical endpoints, which are highly confounded by very complex factors.” The use of biomarkers in developing successful